Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINT
2023-510006-40-00Phase 3Authorised
- Sponsor
- Horizon Therapeutics
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) and Muscle-Specific Tyrosine Kinase Antibody-Positive Myasthenia Gravis (MuSK-MG) comparing Inebilizumab with Placebo (2 arms). Primary endpoint: Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score. Planned start May 2024; status: authorised.
02
Drugs
inebilizumab
03
Conditions
myasthenia gravis (MG)Muscle-Specific Tyrosine Kinase Antibody-Positive Myasthenia Gravis (MuSK-MG)
Beyond the preview
Go deeper on 2023-510006-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510006-40-00.